<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34023632</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8952</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology</Title><ISOAbbreviation>Clin Neurophysiol</ISOAbbreviation></Journal><ArticleTitle>Neurophysiological indices in amyotrophic lateral sclerosis correlate with functional outcome measures, staging and disease progression.</ArticleTitle><Pagination><StartPage>1564</StartPage><EndPage>1571</EndPage><MedlinePgn>1564-1571</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinph.2021.02.394</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1388-2457(21)00492-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study examined neurophysiological (NI), split-hand (SI) and split-leg (SLI) index in patients with amyotrophic lateral sclerosis (ALS), and their correlation with functional status, disease duration, staging and survival.</AbstractText><AbstractText Label="METHODS">Eighty-two patients underwent nerve conduction study to analyze NI, SI and SLI. Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), disease progression rate (&#x394;FS), Milano-Torino (MiToS) and King's staging systems, Forced Vital Capacity (FVC), and survival data were collected.</AbstractText><AbstractText Label="RESULTS">Both NI and SI indices were significantly associated with ALSFRS-R, MiToS, King's and FVC. Slow progressor patients (&#x394;FS&#x202f;&lt;&#x202f;0.5) reported a significantly higher NI and SI values compared to both normal (0.5&#x202f;&#x2264;&#x202f;&#x394;FS&#x202f;&lt;&#x202f;1.00) and fast progressors (&#x394;FS&#x202f;&#x2265;&#x202f;1.0). After dichotomizing patients in slow progressors (&#x394;FS&#x202f;&lt;&#x202f;0.5) and not-slow progressors (&#x394;FS&#x202f;&#x2265;&#x202f;0.5), a combination of SI index and disease duration revealed to be the best prediction model to discriminate patients in accordance with their disease progression (c-index: 0.92), leading to a new prognostic index: the 'Split-Hand prognostic index' (SHpi).</AbstractText><AbstractText Label="CONCLUSION">SI and NI are correlated with functional status and FVC. SHpi index could represent an useful tool to discriminate patients in accordance with their disease progression.</AbstractText><AbstractText Label="SIGNIFICANCE">These data provide novel evidence of neurophysiological indices as promising biomarkers in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barp</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162 Milano, Italy; Neurorehabilitation Unit, University of Milan, Italy. Electronic address: christian.lunetta@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lizio</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Electronic address: andrea.lizio@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerardi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Electronic address: francesca.gerardi@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlarini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Electronic address: claudia.tarlarini@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauro</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Electronic address: luca.mauro@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sansone</LastName><ForeName>Valeria Ada</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Electronic address: valeria.sansone@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre, Fondazione Serena Onlus, Piazza Ospedale Maggiore 3, 20162 Milano, Italy; NeMO LAB S.r.l., Milan Italy. Electronic address: christian.lunetta@centrocliniconemo.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurophysiol</MedlineTA><NlmUniqueID>100883319</NlmUniqueID><ISSNLinking>1388-2457</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Neurophysiological index</Keyword><Keyword MajorTopicYN="N">Prediction model</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Split-hand index</Keyword><Keyword MajorTopicYN="N">Split-leg index</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest CL received compensation for occasional scientific consulting from Neuraltus, Cytokinetics, Mitsubishi Tanabe Pharma Europe and Italfarmaco and has received funds from ARISLA and Italian Ministry of Health. VAS participates in Advisory Boards or Teaching activities for Biogen, Roche, Avexis, PTC, Santhera, Sarepta, Dyne. The remaining authors have nothing to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>23</Day><Hour>20</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34023632</ArticleId><ArticleId IdType="doi">10.1016/j.clinph.2021.02.394</ArticleId><ArticleId IdType="pii">S1388-2457(21)00492-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>